Guidelines

European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for Stage IV lung carcinoma with EGFR-activating mutation4

ESMO Clinical Practice Guidelines recommend DACOPLICE® as one of the first options for Stage IV lung carcinoma with EGFR-activating mutation.4,5

ESMO treatment algorithm4

ESMO treatment algorithm

 Adapted from Planchard D, et al. Ann Oncol. 2018;29(Suppl. 4):iv192–iv237. Update published 18 September2019 bythe ESMOGuidelines Committee. Accessed 22 April 2020. Available from https://www.esmo.org/conte nt/down load/22 745 3/ 3874 538/1 

DACOPLICE®  may preserve targeted treatment options for tumors thatdevelop the T790M resistance mutation6,7
 
 

*MCBS score for the combination of bevacizumab with gefitinib or erlotinib.4
†Not EMA-approved.4
The levels of evidence and grades of recommendation are shown from the ESMO guidelines.4 The ESMO-MCBS is a standardized, validated approach that helps to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer treatments. The scale is graded 1-5 (Grades 4 and 5 represent a high level of proven clinical benefit).8 Version 1.1 of the ESMO-MCBS has been used here.4

Abbreviations: CfDNA: Cell-free Deoxyribonucleicacid, ChT: Chemotherapy, CI: Confidence Interval, EGFR: Epidermal Growth Factor Receptor, EMA: European Medicines Agency, ESMO: European Society for Medical Oncology, HR: Hazard Ratio, IRC: Independent Radiological Central, MCBS: Magnitude of Clinical Benefit Scale, PS: Performance Status, RT: Radiotherapy, TKI: Tyrosine Kinase Inhibitor

References:

  1. Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(11):1454-1466.
  2. Mok TS, Cheng Y, Zhou X, et al. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. Drugs. 2021;81(2):257-266.
  3. Local Prescribing Document for DACOPLICE®. LPD Version 4. Pfizer India_LPDDAC042021.
  4. Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Updated version published 18 September2019 by the ESMO Guidelines Committee. Ann Oncol. 2018;29(suppl 4):iv192-iv237.
  5. ESMO.org. 2020. EMA recommends Granting A Marketing Authorization For Dacomitinib.[online] Available at: <http://www.esmo.org/oncology-news/EMA-Recommends-Granting-a-Marketing- Authorization-for-Dacomitinib> [Accessed 22 July 2021].
  6. Girard N. Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when? Future Oncol. 2018;14(11):1117-1132.
  7. Hirsh V. Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors. Ther Adv Med Oncol. 2018;10:1-12.
  8. Cherny NI, Dafni U, Bogaerts J et al. ESMO Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol. 2017;28:2340-2366.

Please click on Prescribing Information link to view safety and adverse events information of DACOPLICE®. For the use only of registered medical practitioner, or a hospital or a laboratory.
 

PP-DAC-IND-0093 22-07-2021